Linagliptin Zentiva

Linagliptin, the active ingredient in Linagliptin Zentiva, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as a tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve glycaemic control when used with diet and exercise.

GNH USA supplies Linagliptin Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet the needs of healthcare providers across multiple regions.

Linagliptin is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus.

- Type 2 diabetes mellitus (monotherapy): lowers blood glucose and HbA1c when diet and exercise alone are insufficient. - Type 2 diabetes mellitus (combination with metformin): provides additional glucose reduction beyond metformin alone. - Type 2 diabetes mellitus (add‑on to insulin): helps reduce required insulin dose while maintaining glycaemic control. - Type 2 diabetes mellitus (adjunct to other oral agents): offers complementary glucose‑lowering effect in multi‑drug regimens.

Linagliptin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nasopharyngitis: mild upper‑respiratory infection symptoms. - Headache: transient mild to moderate pain. - Dizziness: occasional light‑headedness. - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Upper respiratory tract infection: cough or sore throat.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe hypersensitivity reactions: rash, angioedema, or anaphylaxis. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Severe hypoglycaemia: especially when combined with insulin or sulfonylureas. - Bullous pemphigoid: rare autoimmune skin disorder.

Before initiating Linagliptin, consider the following safety measures.

- Renal impairment: monitor kidney function and adjust therapy if necessary. - Hepatic impairment: use with caution and observe liver function tests. - Hypersensitivity: discontinue the drug if rash, swelling, or anaphylactic signs develop. - Pregnancy: safety not established; avoid unless clearly needed. - Elderly patients: monitor for dehydration and renal function. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Linagliptin may interact with other medicines; assess the risk level before co‑administration.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase linagliptin exposure. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce linagliptin effectiveness.

Moderate Interactions (Monitor Closely): - Diuretics: increased risk of dehydration, which can affect glucose control. - Insulin or sulfonylureas: heightened risk of hypoglycaemia; dose adjustments may be required. - Rifampin (moderate inducer): may modestly lower linagliptin plasma levels. - Antihypertensive agents: monitor blood pressure as fluid shifts may occur.